Related Experiment Videos
Targeting antigens to antigen presenting cells.
S Fossum1, S F Berg, S Mjaaland
1Department of Anatomy, University of Oslo, Norway.
Seminars in Immunology
|August 1, 1992
Summary
Targeting antigens to antigen presenting cells (APCs) using monoclonal antibodies enhances immune responses. This novel immunotargeting method shows potential for vaccination and inducing tolerance without adjuvants.
Area of Science:
- Immunology
- Biotechnology
Background:
- Antigen delivery to antigen presenting cells (APCs) can be achieved by conjugating antigens to monoclonal antibodies targeting APC surface molecules.
- Existing research demonstrates that immunotargeting amplifies humoral immune responses.
Purpose of the Study:
- To review current research on antigen targeting to APCs.
- To discuss the mechanisms underlying the immune-enhancing effects of immunotargeting.
- To explore the potential clinical applications of immunotargeting, including vaccination and tolerance induction.
Main Methods:
- Conjugating antigens to monoclonal antibodies against APC surface molecules.
- Administering low antigen doses without adjuvants.
- Analyzing humoral immune responses.
- Investigating potential for immune response modulation.
Main Results:
- Immunotargeting enhances humoral responses effectively, even with low antigen doses and without adjuvants.
- Preliminary data suggest the method can direct immune responses and potentially induce tolerance.
- The efficacy depends on the targeted ligand and cell type.
Conclusions:
- Antigen targeting to APCs is a potent method for enhancing immune responses.
- This approach holds promise for future clinical applications, particularly in vaccine development and immune tolerance.
- Further research is needed to fully elucidate the mechanisms and optimize clinical use.